The Evergreening Myth Isnt the StoryThe Patent Thicket Is.
If youve spent any time around pharma policy, generics, or patent litigation, youve probably heard the phrase evergreening. Its used like a catch-all: newer filings, minor tweaks, defensive pat…
The Evergreening Myth: How to Spot the Cracks in a 20-Patent Thicket Read Post »
If youve ever watched a patent case drag on for years, you already know the obvious ROI story: win in court, collect leverage, move on.
But theres a quieter, often undercounted ROI story that shows up in the backgroundespecially in method-of-use (MoU) …
Sue Early, Win Big: The Hidden ROI of Challenging Weak Method-of-Use Drug Patents Read Post »
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
In pharma, first-to-file is often treated like a cheat code.
File an Abbreviated New Drug Application (ANDA) first, trigger the 180-day exclusivity clock, outpace competitors, and…
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money Read Post »
Most pharma teams treat settlement like a win button. In court, that mindset is expensive.
Theres a familiar script in drug litigation: if the dispute is hard, settle. If the numbers look uncertain, settle. If the optics get messy, settle.
But drug…
Your drug patent fortress may look impregnableuntil the device patent cracks are found.
Thats the uncomfortable insight behind a growing reality in pharma IP strategy: device patents often become the first line of attack not because theyre more importa…
Why Device Patents Crack First: The Weakest Wall in Your Drug’s Patent Fortress Read Post »
A new patent can sometimes be a lossnot a breakthrough.
Thats the uncomfortable lesson behind whats often called the salt change trap: a situation where a seemingly fresh patent emerges, but the underlying medicineand therefore the practical impact o…
The Salt Change Trap: When a New Patent Buys You Nothing Read Post »
Six months sounds like a victory lapuntil you see what it does to families, competition, and innovation.
In the U.S. drug approval ecosystem, pediatric exclusivity is often framed as a moral imperative: reward companies for running pediatric studies, a…
The Six-Month Fuse: Why Pediatric Exclusivity Is a Liability, Not a Shield Read Post »
Bausch Healths legal win wasnt just about one caseit was a signal about how pharma is defending value in an era of accelerating generic entry.
In Bausch Health Companies Inc. v. Sun Pharmaceutical Industries Ltd., the dispute highlights a reality many …
BAUSCH HEALTH COMPANIES INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD. Read Post »
Exelixis vs. Intas: When Generic Isnt a WordIts a Strategy
Theres a recurring misunderstanding in biotech: that generic competition is a straight linepatents fall, approvals follow, prices drop.
In reality, the biotech IP battleground is often a labyri…
Patent Litigation Isnt Just DramaIts a Pricing Strategy
If youve ever wondered how drug prices movequietly, predictably, and sometimes abruptlyit often starts not in the pharmacy, but in a courtroom.
Thats the takeaway from Amneal Pharmaceuticals, LLC …
Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd. Read Post »
Get new actionable insights and updates from BiotechBlog
